10 results
To identify the influence of two different biocompatible-coated extracorporeal circuits on the perfused boundary region of the sublingual microvasculature as measured by the GlycoCheck Sidestream Darkfield Imaging camera.
To compare which treatment (indwelling catheter versus intermittend catheterisation) has the best clinical effect in women with symptomatic PUR.
The objective of this study is to evaluate the efficacy and safety of adalimumab 80 mg loading dose followed by 40 mg dose given every other week (eow) subcutaneously (SC) starting at Week 1 compared with placebo as maintenance therapy in subjects…
The objective of this study is to evaluate the efficacy and safety of adalimumab 80 mg loading dose followed by 40 mg dose given every other week (eow) subcutaneously (SC) starting at Week 1 compared with placebo in subjects with inactive non-…
The reliability of the Bladderscan in the postpartum period and the prevalence of asymptomatic postpartum urinary retention.
To evaluate the effectiveness and safety of concentration controlled combination of once daily dosed low-dose sirolimus (trough levels: 3-5 ng/ml) and extended-release tacrolimus (trough levels:3-5 ng/ml), in order to provide superior renal function…
With intervention with bronchodilators (usual care bronchodilators for COPD subjects), in one study histamine and in one study steroids, we want to investigate the respons on inspiratory lung function parameter like the FIV1 and also investigate…
To define and implement an uniform initial evaluation and stratification on adult patients with LCH, to uniform the treatment of adult patients with LCH and to improve treatment results with respect to survival, therapy response, prevention of…
In this pilot study we have technical/methodological questions: we want to confirm the envisioned kinetic profiles of stable isotope tracers 13C-labelled SCFA delivered by catheter in 5 subjects, and to establish the time points of plasma sampling (…
To compare pembrolizumab plus docetaxel plus prednisone to placebo plus docetaxel plus prednisone with respect to overall survival (OS)